erlotinib has been researched along with clofarabine in 3 studies
| Studies (erlotinib) | Trials (erlotinib) | Recent Studies (post-2010) (erlotinib) | Studies (clofarabine) | Trials (clofarabine) | Recent Studies (post-2010) (clofarabine) |
|---|---|---|---|---|---|
| 221 | 0 | 180 | 424 | 101 | 280 |
| Protein | Taxonomy | erlotinib (IC50) | clofarabine (IC50) |
|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 3.12 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
2 review(s) available for erlotinib and clofarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |
1 other study(ies) available for erlotinib and clofarabine
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |